Торможение прогрессирования почечной дисфункции и церебровоскулярных событий: возможности Аторвастатина


И.Т. Муркамилов (1, 2), К.А. Айтбаев (3), В.В. Фомин (4), З.Р. Райимжанов (5), Н.А. Реджапова (6), Ф.А. Юсупов(6), З.А. Айдаров (1)

1) Кыргызская государственная медицинская академия им. И.К. Ахунбаева, Бишкек
2) Кыргызско-Российский Славянский университет им. первого Президента России Б.Н. Ельцина, Бишкек
3) Научно-исследовательский институт молекулярной биологии и медицины, Бишкек
4) ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России, Москва
5) ФГКУ «Главный военный клинический госпиталь им. акад. Н.Н. Бурденко» Министерства обороны РФ, Москва
6) Ошский государственный университет, Ош

В статье обсуждаются патогенетические механизмы формирования почечной дисфункции при гиперлипидемии. Представлены данные по изучению роли статинов, в частности аторвастатина, в прогрессировании нефроцеребральных взаимоотношений. Про‐ анализированы результаты ряда исследований, свидетельствующих о нефро‐ и церебропротективных свойствах аторвастатина.

Литература


1. Фомин В.В., Рогова И.В., Дамулин И.В., Мухин Н.А. Особенности формирования когнитивных расстройств на додиализных стадиях хронической болезни почек. Журнал неврол. и психиатр. им. С.С. Корсакова. 2015;12:25–30.

2. Рогова И.В., Фомин В.В., Дамулин И.В., Мухин Н.А. Умеренные когнитивные расстройства при хронической болезни почек: клинико-патогенетические особенности, факторы риска, лечение. Клин. нефрология. 2012;5:4–8.

3. Laurent S., Boutouyrie P. Arterial stiffness: a new surrogate end point for cardiovascular disease? J. Nephrol. 2007;20(12):45–50.

4. Ni J., Ma K. L., Wang C.X., Liu J., Zhang Y., Lv L.L., Ni H.F., Chen Y.X., Ruan X.Z., Liu B.C. Activation of renin-angiotensin system is involved in dyslipidemia-mediated renal injuries in apolipoprotein E knockout mice and HK-2 cells. Lipids in health and disease. 2013;12(1):49.

5. Favre G.A., Esnault V.L.M., Van Obberghen E. Modulation of glucose metabolism by the renin-angiotensin-aldosterone system. Am. J. Physiol.-Endocrin. Metabol. 2015;308(6):435–49.

6. Мухин Н.А., Фомин В.В., Дамулин И.В., Рогова И.В. Хроническая болезнь почек и сосудистая деменция. Тер. архив. 2014;6:7– 10.

7. Nayak-Rao S., Shenoy M.P. Stroke in patients with chronic kidney disease. How do we approach and manage it? Ind. J. Nephrol. 2017;27:167–71.

8. Moorhead J.F., Chan M.K., El-Nahas M., Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2:1309–11.

9. Смирнов А.В. Характеристика дислипопротеидемий у больных гломерулонефритом. Нефрология. 1998;2(3):76–83.

10. Wheeler D.C., Chana R.S: Interactions between lipoproteins, glomerular cells and matrix. Miner. Electrolyte Metab. 1993; 19(3);149–64.

11. Kramer-Guth A., Nauck M., Pavenstädt H., Königer M., Wieland H., Schollmeyer P., Wanner C. Preferential uptake of intermediatedensity lipoproteins from nephrotic patients by human mesangial and liver cells. J. Am. Soc. Nephrol. 1994;5:1081–90.

12. Joles J.A., Kunter U.T.A., Janssen U., Kriz W., Rabelink T.J., Koomans H.A., Floege J. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J. Am. Soc. Nephrol. 2000;11(4):669–83.

13. Тареева И.Е. Нефрология. Руководство для врачей. 2000. 688 с.

14. Моисеев В.С., Мухин Н.А., Смирнов А.В., Кобалава Ж.Д., Бобкова И.Н., Виллевальде С.В., Ефремовцева М.А., Козловская Л.В., Швецов М.Ю., Шестакова М.В., Арутюнов Г.П. и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Клин. фармакология и терапия. 2014;23(3):4–27.

15. Mikolasevic I., Žutelija M., Mavrinac V. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int. J. Nephrol. Renovasc. Dis. 2017;10:35–45. doi:10.2147/IJNRD.S101808.

16. Honore P.M., Jacobs R., Hendrickx I., De Waele E., Van Gorp V., De Regt J., Spapen H.D. Statins and the Kidney: Friend or Foe? Blood Purif. 2017;43(1–3):91–6.

17. de Zeeuw D., Anzalone D.A., Cain V.A., Cressman M.D., Heerspink H.J., Molitoris B.A., Monyak J.T., Parving H.H., Remuzzi G., Sowers J.R.,Vidt D.G. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The lancet Diabetes & endocrinology. 2015;3(3):181–90.

18. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., Agewall S., Alegria E., Chapman M.J., Durrington P., Erdine S., Halcox J., Hobbs R., Kjekshus J., Filardi P.P., Riccardi G., Storey R.F., Wood D. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011;32:1769–818.

19. Chaplin S. NICE statins guidance: prevention of cardiovascular events. Prescriber. 2006;17(4):58–60.

20. Jones P.H. Comparing HMG-GoA reductase inhibitors. Clin. Cardiol. 2003;26:115–20.

21. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 1990; 343:425–30.

22. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S., Landmesser U., Pedersen T.R., Reiner Ž., Riccardi G., Taskinen M.R., Tokgozoglu L., Verschuren W.M., Vlachopoulos C., Wood D.A., Zamorano J.L. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J. 2016;37(39):2999–3058.

23. Krenning G., Dankers P.Y., Drouven J.W., Waanders F., Franssen C.F., van Luyn M.J., Harmsen M.C., Popa E.R. Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. Am. J. Physiol.-Renal Physiol. 2009;296(6):1314– 22.

24. Imig J.D., Ryan M.J. Immune and inflammatory role in renal disease. Comprehensive Physiol. 2013;3(2):957–76.

25. Vianna H.R., Soares C.M., Tavares M.S., Teixeira M.M., Silva A.C. Inflammation in chronic kidney disease: the role of cytokines. J. Bras. de Nefrol. 2011;33(3):351–64.

26. Wu K., Tian S., Zhou H., Wu Y. Statins protect human endothelial cells from TNF-induced inflammation via ERK5 activation. Bioch. Pharmacol. 2013;85(12):1753–60.

27. Loppnow H., Zhang L., Buerke M., Lautenschläger M., Chen L., Frister A., Schlitt A., Luther T., Song N., Hofmann B., Rose-John S., Silber R.E., Müller-Werdan U., Werdan K. Statins potently reduce the cytokine‐mediated IL‐6 release in SMC/MNC cocultures. J. Cell. Molec. Med. 2011;15(4):994–1004.

28. Siems W., Quast S., Carluccio F., Wiswedel I., Hirsch D., Augustin W., Kraemer K., Hampl H., Sommerburg O. Oxidative stress in chronic renal failure as a cardiovascular risk factor. Clin. Nephrol. 2002;58(1):12–9.

29. Mück A.O., Seeger H., Wallwiener D. Classspecific pro-apoptotic effect of statins on human vascular endothelial cells. Z. Kardiol. 2004;93(5):398–402.

30. Fried L.F., Orchard T.J., Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta.analysis. Kidney Int. 2001;59(1):260–69.

31. Strippoli G.F., Navaneethan S.D., Johnson D.W., Perkovic V., Pellegrini F., Nicolucci A., Craig J.C. Effects of statins in patients with chronic kidney disease: meta-analysis and metaregression of randomised controlled trials. BMJ. 2008;336(7645):645–51.

32. Athyros V., Papageorgiou A., Mercouris B. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus “usual” care in secondary coronary heart desease prevention. The GREACE study. Curr. Med. Res. Opin. 2002;18(4):220–28.

33. Isaacsohn J.L., Davidson M.H., Hunninghake D., Singer R., McLain R., Black D.M. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) – rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am. J. Cardiol. 2000;86(2):250–52.

34. Wright J., Hutchison A. Cardiovascular disease in patients with chronic kidney disease Vasc. health and risk management. 2009; 5:713–22.

35. Locatelli F., Pozzoni P., Tentori F., del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephr. Dial. Transpl. 2003;18(7):2vii9.

36. Segall L., Nistor I., Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Bio. Med. Research. Int. 2014.

37. Takagi H., Umemoto T. Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials. Int. J. Cardiol. 2012;155(2):296–99.

38. Mozaffarian D., Nye R., Levy W. Statin therapy is associated with lower mortality among patients with severe heart failure. Am. J. Cardiol. 2004;93(9):1124–29.

39. Khush K.K., Waters D.D., Bittner V., Deedwania P.C., Kastelein J.J., Lewis S.J., Wenger N.K. Effect of high-dose atorvastatin on hospitalizations for heart failure. Circulation. 2007;115(5):576–83.

40. Scirica B.M., Morrow D.A., Cannon C.P., Ray K.K., Sabatine M.S., Jarolim P., Shui A., McCabe C.H., Braunwald E. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT–TIMI 22 study. J. Am. Coll. Card. 2006;47(11):2326–31.

41. Kasama S., Toyama T., Sumino H., Kumakura H., Takayama Y., Minami K., Ichikawa S., Matsumoto N., Sato Y., Kurabayashi M. Prognostic value of cardiac sympathetic nerve activity evaluated by

42. Tsutamoto T., Sakai H., Ibe K., Yamaji M., Kawahara C., Nakae I., Fujii M., Yamamoto T., Horie M. Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in nondiabetic patients with dilated cardiomyopathy. Circ. J. 2011;75(9):2160–6.

43. Shepherd J., Kastelein J., Bittner V., Deedwania P., Breazna A., Dobson S., Wilson D.J., Zuckerman A., Wenger N.K. Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin. J. Am. Soc. Nephrol. 2007;2(6):1131–39.

44. Бондар К.Ю., Белая О.Л., Лазутина О.М., Куроптева З.В., Байдер Л.М., Артамошина Н.Е., Яковлева Т.В. Гендерные особенности антиоксидантной защиты и эффективность аторвастатина у больных со стабильными формами ишемической болезни сердца. Клин. мед. 2017;5(95):398–403.

45. Shepherd J., Kastelein J.P., Bittner V.A., Deedwania P.C., Breazna A., Dobson S., Wilson D.J., Zuckerman A.L., Wenger N.K. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Cli. Proc. 2008;83(8):870–79.

46. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men. Circulation. 2000;101(15):1767–72. PMID:10769275.

47. Wahre T., Yundestat A., Smith C., Haug T., Tunheim S.H., Gullestad L., Frøland S.S., Semb A.G., Aukrust P., Damås J.K. Increased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors. Circulation. 2004;109(16):1966–72.

48. Schonebeck U., eVaro N., Libby P., Buring J., Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation. 2001; 104:2266–68.

49. Kinlay S., Schwartz G.G., Olsson., Rifai N., Sasiela W.J., Szarek M., Ganz P., Libby P. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in Myocardial Ischemia Reduction and Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110:386–91.

50. Blanco-Colio L.M., Тuñón J., MartínVentura J.L., Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63(1);12–23.

51. Charo I.F., Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis Nature Rev. Drug Discovery. 2011;10(5):365–76.

52. Popa C., Netea M.G., Van Riel P.L., van der Meer J.W., Stalenhoef A.F. The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lip. Res. 2007;48(4):751–62.

53. Bianchi S., Bigazzi R., Caiazza A., Campese V. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am. J. Kidney Dis. 2003;41(3):565–70.

54. Bemelmans M.H., Gouma D.J., Buurman W.A. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J. Immunol. 1993;150(5):2007–17.

55. Hession C., Decker J.M., Sherblom A.P., Kumar S., Yue C.C., Mattaliano R.J., Tizard R., Kawashima E., Schmeissner U., Heletky S., et al. Uromodulin (Tamm-Horsfall glycoprotein): A renal ligand for lymphokines. Science. 1987;237(4821):1479–84.

56. Banyai S., Banyai M., Falger J., Jansen M., Alt E., Derfler K., Koppensteiner R. Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on longterm LDL apheresis treatment. Atheroscleros. 2001;159:513–19.

57. Haque T., Khan B.V. Atorvastatin: a review of its pharmacological properties and use in familial hypercholesterolemia. Clinical Lipidology. 2010;5(5):615–25.

58. Woodward M., Lowe G.D., Rumley A., TunstallPedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle aged men and women. The Scottish Heart Health Study. Eur. Heart J. 1998;19:55–62.

59. Zheng C., Azcutia V., Aikawa E., Figueiredo J.L., Croce K., Sonoki H., Sacks F.M., Luscinskas F.W., Aikawa M. Statins suppress apolipoprotein CIIIinduced vascular endothelial cell activation and monocyte adhesion. Eur. Heart J. 2013;34(8):615–24.

60. Ridker P.M., Cannon C.P., Morrow D.A., Rifai N., Kirtane A.J., McCabe C.H., Skene A.M., Gibson C.M., Ridker P.M., Braunwald E. for PROVE IT– TIMI 22 Investigators. C–reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 2005;352(1):20–8.

61. Nissen S.E., Tuzcu E., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., Orazem J., Magorien R.D., O’Shaughnessy C., Ganz P. for REVERSAL Investigators. Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. N. Engl. J. Med. 2005;352(1):2938.

62. Сусеков А.В., Рожкова Т.А., Трипотень М.И., Зубарева М.Ю., Рожкова Т.А., Погорелова О.А., Балахонова Т.В., Масенко В.П., Кухарчук В.В. Рандомизированное исследование ФАРВАТЕР. Часть 2. Влияние аторвастатина 10 и 20 мг/сут на функцию эндотелия, растяжимость и жесткость сосудистой стенки. Кардиология. 2007;2:25–30.

63. Беспалова И.Д., Калюжин В.В., Рязанцева Н.В., Медянцев Ю.А., Мурашев Б.И., Осихов И.А. Влияние 8-недельной терапии аторвастатином на качество жизни больных гипертонической болезнью с метаболическим синдромом. Артериальная гипертензии. 2013;19(2):125–31.

64. Кошельская О.А., Винницкая И.В., Конько Т.Ю., Кравченко Е.С., Суслова Т.Е., Карпов Р.С. Сравнительное рандомизированное исследование по оценке влияния длительной терапии розувастатином в сочетании с комбинацией аторвастатина и эзетимиба на показатели углеводного обмена и уровень адипокинов у больных ишемической болезнью сердца и сахарным диабетом 2 типа. Кардиология. 2015;3:67–74.

65. Соломенчук Т.Н., Семеген-Бодак К.В., Слаба Н.А., Чнгрян, Г.В., Мысышин М.Б. Проатерогенные метаболические нарушения при хронической болезни почек недиабетического генеза: возможности коррекции статинами. Кардиология. 2014;6:40–3.

66. Скорюкова С.А., Ким М.В., Быстрова А.А., Баранова Е.И., Пчелина С.Н. Полиморфизм S19W гена аполипопротеина А5 и эффективность терапии аторвастатином и фенофибратом у больных сахарным диабетом 2-го типа. Артериальная гипертензия. 2015;21(6):595–603.

67. Wang Y., Qiu X., Lv L., Wang C., Ye Z., Li S., Liu Q., Lou T., Liu X. Correlation between Serum Lipid Levels and Measured Glomerular Filtration Rate in Chinese Patients with Chronic Kidney Disease. Cheng X, ed. PLoS ONE. 2016;11(10):e0163767.

68. Widiasta A., Pardede S.O., Rachmadi D. Correlation between LDL, HDL, Total Cholesterol, and Triglyceride with the Degree of Chronic Kidney Disease in Children. Am. J. Clin. Med. Res. 2017;5(1):1–5.

69. Masse I., Bordet R., Deplanque D., Al Khedr A., Richard F., Libersa C., Pasquier F. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 2005.76(12). 1624–29.

70. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., CharltonMenys V., Fuller J.H. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435): 685–96.

71. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O’Brien E., Ostergren J. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-thanaverage cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.

72. Sever P., Dahlöf B., Poulter N., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S., Kristinsson A., McInnes G., Mehlsen J., Nieminem M., O’Brien E., Ostergren J. ASCOT Steering Committee Members. Potential synergy between lipid-lowering and bloodpressurelowering in the Anglo Scandinavian Cardiac Outcomes Trial. Eur. Heart J. 2006;27(24):2982–88.

73. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA. 2001;285:1711–18.

74. Оганов Р.Г., Аронов Д.М, Бубнова М.Г. Применение статинов – парадигма профилактики и лечения атеросклеротических заболеваний (фокус на аторвастатин). Кардиоваск. терапия и профилактика. 2006;6:95–107.

75. Wanner C., Tonelli M. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303–309.

76. Mancia G., Fagard R., Narkiewicz K., Redón J., Zanchetti A., Böhm M., Christiaens T., Cifkova R., De Backer G., Dominiczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J., Nilsson P.M., Ruilope L.M., Schmieder R.E., Sirnes P.A., Sleight P., Viigimaa M., Waeber B., Zannad F. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013;34(28):2159–219.

77. American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes care. 2013;36(1):11–66.

78. Pliquett R.U., Cornish K.G., Zucker I.H. Statin therapy restores sympathovagal balance in experimental heart failure. J. Appl. Physiol. 2003;95(2):700–4.

79. Van der Harst P., Wagenaar L.J., Buikema H., Voors A.A., Plokker H.W., Morshuis W.J., Six A.J., Boonstra P.W., Nickenig G., Wassmann S., van Veldhuisen D.J., van Gilst W.H. Effect of intencive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease. Am. J. Cardiol. 2005;96(10):1361–64.

80. Pavlović J., Greenland P., Deckers J.W., Brugts J.J., Kavousi M., Dhana K., Ikram M.A., Hofman A., Stricker B.H., Franco O.H., Leening M.J. Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular DiseaseResults From the Population-Based Rotterdam Study. JAMA. Cardiol. 2016;1(6):708–13.

81. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M. Jr., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl. J. Med. 2008;359:2195–207.

82. Tendolkar I., Enajat M., Zwiers M.P., van Wingen G., de Leeuw F.E., van Kuilenburg J., Bouwels L., Pop G., Pop-Purceleanu M. Oneyear cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial. Int. J. Geriatr. Phychiatry. 2012;27(1):49–58.

83. März W., Genser B., Drechsler C., Krane V., Grammer T.B., Ritz E., Stojakovic T., Scharnagl H., Winkler K., Holme I., Holdaas H., Wanner C. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 2011;6(6):316–325.

84. Arvanitakis Z., Schneider J.A., Wilson R.S., Bienias J.L., Kelly J.F., Evans D.A., Bennett D.A. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70(19, 2):1795–802.

85. Beck M. Can a drug that helps hearts be harmful to the brain? Wall Street J. 2008 February 12 (Available at: http://online.wsj. com/public/us).

86. Barone E., Cenini G., Di Domenico F., Martin S., Sultana R., Mancuso C., Murphy M.P., Head E., Butterfield D.A. Long-term highdose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol. Res. 2011;63(3):172–80.

87. Yan Y., Qiu B., Wang J., Deng S.B., Wu L., Jing X.D., Du J.L., Liu Y.J., She Q. Highintensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. BMJ. Open. 201;5: e006886.

88. Wu Y.L., Saver J.L., Chen P.C., Lee J.D., Wang H.H., Rao N.M., Lee M., Ovbiagele B. Effect of statin use on clinical outcomes in ischemic stroke patients with atrial fibrillation. Medicine. 2017;96(5):e5918.

89. Kostapanos M.S., Liberopoulos E.N., Goudevenous J.A., Mikhailidis D.P., Elisaf M.S. Do statins have an antiarrhythmic activity? Cardiovas. Res. 2007;75:10–20.

90. Pretorius M., Donahue B.S., Yu C., Greelish J.P., Roden D.M., Brown N.J. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation. 2007;116(1):1–7.

91. Roik M., Starczewska M.H., Huczek Z. Statin therapy and mortality among patients hospitalized with heart failure and preserved left ventricular function - a preliminary report. Acta Cardiol. 2008;63(6):683–92.

92. Cho E. Y., Myoung C., Park H. S., Kim A.J., Ro H., Chang J.H., Lee H.H., Chung W., Jung J.Y. Efficacy of Statin Treatment in EarlyStage Chronic Kidney Disease. PloS One. 2017;12(1):e0170017.


Об авторах / Для корреспонденции


Автор для связи: И.Т. Муркамилов – к.м.н., врач-нефролог I квалификационной категории, ассистент кафедры факультетской терапии Кыргызской государственной медицинской академии им. И.К. Ахунбаева, Бишкек; e-mail: murkamilov.i@mail.ru


Похожие статьи


Бионика Медиа